Randomized, Double-Blinded Multicenter Study

Comparison of Intracoronary Single-Chain Urokinase-Type Plasminogen Activator, Pro-urokinase (GE-0943), and Intracoronary Urokinase in Patients With Acute Myocardial Infarction

Hirofumi Kambara, MD, Chuichi Kawai, MD, Nagao Kajiwara, MD, Hirokazu Niitani, MD, Shigetake Sasayama, MD, Katsuo Kannatsuse, MD, Kazuhisa Kodama, MD, Hikaru Sato, MD, Masakiyo Nobuyoshi, MD, Mitsuyoshi Nakashima, MD, Osamu Matsuo, MD, and Tamotsu Matsuda, MD

Coronary recanalization rates and changes in the coagulation and fibrinolysis system were evaluated in a randomized fashion in patients with acute myocardial infarction after intracoronary administration of single-chain urokinase-type plasminogen activator (pro-urokinase: GE-0943) or urokinase. Three groups of patients were studied: group H (n = 50), 6,000 units pro-urokinase i.c.; group L (n = 44), 3,000 units pro-urokinase i.c.; and group U (n = 54), 960,000 IU urokinase i.c. Coronary recanalization rates determined angiographically after 45 minutes of intracoronary infusion averaged 90% in group H, 59% in group L, and 61% in group U. The differences were statistically significant between group H and the latter two groups. Pro-urokinase affected plasma proteins of the fibrinolytic system to a lesser degree than urokinase. Bleeding complications were present in one patient in group L, in none in group H, and in five in group U. Thus, intracoronary administration of 6,000 units pro-urokinase is more effective in coronary thrombolysis and causes less systemic fibrinogenolysis than intracoronary administration of urokinase. (Circulation 1988;78:899–905)

Rapid and effective dissolution of intracoronary thrombi by systemic or selective infusion of thrombolytic agents has been demonstrated convincingly in many clinical studies. In Japan, we initiated a multicenter clinical trial of intracoronary administration of urokinase to aim at early recanalization of the infarct-related coronary arteries in 1982. In 1984, a randomized double-blinded, placebo-controlled study was started to assess early recanalization of infarct-related vessels with intracoronary urokinase in patients with acute myocardial infarction. The patency rate was 74% for the urokinase group and 17% for the placebo group. However, urokinase possesses little specific affinity for fibrin and, therefore, will activate both circulating and fibrin-bound plasminogen, possibly resulting in serious bleeding complications.

Single-chain urokinase-type plasminogen activator (pro-urokinase: GE-0943)13-15 is a plasminogen proactivator secreted by human embryonic kidney cells, which is converted to a two-chain urokinase. Prourokinase does not significantly activate plasminogen in the absence of fibrin, but the addition of a fibrin clot results in efficient fibrinolysis without fibrinogenolysis. In a preliminary study, we reported that intracoronary administration of prourokinase was effective in establishing early recanalization and that the efficacy rate appeared to be dose dependent. No side effects were noted in any patient.
Therefore, we performed this randomized, double-blinded, controlled study to test the efficacy of pro-urokinase and to compare it with urokinase in patients with acute myocardial infarction.

**Patients and Methods**

**Patients**

All patients of the 67 participating institutes in Japan who satisfied the following criteria between May 1987 and November 1987 were enrolled: 1) chest pain characteristic of myocardial ischemia for 30 minutes or more; 2) ST segment elevation of at least 0.1 mV on two or more leads of the electrocardiogram; 3) an elapsed time from the onset of chest pain to the administration of the investigational drugs of less than 6 hours; and 4) angiographically documented complete obstruction of the infarct-related artery.

Patients were excluded if they met any of the following criteria: 1) recanalization after intracoronary administration of nitrates; 2) past or present history of gastrointestinal bleeding or hemorrhagic disorder; 3) significant surgical procedure within 2 weeks; 4) presence of rupture in the papillary muscle or interventricular septum, cardiogenic shock, or any other life-threatening systemic diseases; 5) possible or proven pregnancy; 6) uncontrolled hypertension; and 7) other conditions that the attending physicians considered inappropriate for treatment under this protocol.

**Study Drugs**

*Pro-urokinase.* Each vial contained 750 or 1,500 units lyophilized pro-urokinase, GE-0943, which is a single-chain urokinase-type plasminogen activator.

*Urokinase.* Each vial contained 240,000 IU lyophilized urokinase.

The amidolytic activity of pro-urokinase was determined with S-2444, which is a chromogenic substrate for urokinase, before or after activation by plasmin treatment. The amounts of contamination by urokinase in the pro-urokinase preparations were 0% from the amidolytic activities of pro-urokinase preparations before and after activation by plasmin treatment. Three hundred units pro-urokinase (latent activity) described in this paper was estimated to be equivalent to $1 \times 10^3$ IU urokinase. Both study drugs were prepared by the Green Cross Corporation, Osaka, Japan, and were identical in appearance.

**Study Design**

The study comprised the following three groups of patients: group H, four vials of 1,500 units pro-urokinase, 6,000 units in total, were infused during the treatment; group L, four vials of 750 units pro-urokinase, 3,000 units in total, were infused during the treatment; and group U, four vials of 240,000 IU urokinase, 960,000 IU in total, were infused during the treatment.

Three to 10,000 IU heparin were injected intravenously just before coronary arteriography. The coronary artery that was remote to the infarcted zone was visualized first, followed by cineangiography of the infarct-related artery. If coronary arteriography demonstrated total occlusion, nitrates (200 µg or more of nitroglycerin or isosorbide dinitrate) were given intracoronarily. If the nitrate failed to recanalize the occluded artery, the patient was randomized by a double-blinded method to one of the treatment groups. Each vial of the assigned agent was diluted with 20–40 ml normal saline or 5% dextrose-water and infused intracoronarily during a 10-minute period. After completion of the infusion of each vial, coronary arteriography was repeated to evaluate the degree of recanalization. The degree of recanalization was graded according to the Thrombolysis in Myocardial Infarction trial (TIMI) study as follows: grade 0, no reperfusion; grade 1, thrombolysis without myocardial reperfusion; grade 2, partial reperfusion; and grade 3, full reperfusion.

No concomitant administration of any other plasminogen activator such as urokinase, streptokinase, or tissue-type plasminogen activator was allowed during the period of investigational drug infusion. Subsequent to the coronary cineangiography after the four vials of investigational drug had been given, additional therapies by plasminogen activator, anticoagulation, or percutaneous transluminal coronary angioplasty were permitted if clinically indicated.

**Laboratory Tests**

Fibrinogen, fibrinogen(ogen) degradation products, euglobulin lysis time, and α2-plasmin inhibitor were measured on samples taken before treatment and at the conclusion of administration of the fourth vial of the test drug. Complete blood count and routine blood chemistry were measured at baseline and 24 hours after administration of the test drug.

**Informed Consent and Statistical Analysis**

The study was approved by the human research review committee at each participating institution. Informed consent was obtained from either the patient or the family. Data were expressed as mean ± SD. Analysis of the data was performed with Student’s t test, Kruskal-Wallis’s H test (Sheffe), and χ² test. A p value of less than 0.05 was considered statistically significant.

**Results**

**Patient Data**

A total of 164 patients were studied, 53 in group H, 53 in group L, and 58 in group U. Sixteen patients were excluded from data analysis because of cardiogenic shock at the beginning of investigation in eight patients, administration of the drug more than 6 hours after onset of chest pain in three, subtotal occlusion of the infarct-related artery in
TABLE 1. Patient Clinical Data

<table>
<thead>
<tr>
<th>Variables</th>
<th>Patients (n)</th>
<th>Group H</th>
<th>Group L</th>
<th>Group U</th>
<th>H test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>39–49</td>
<td>7</td>
<td>5</td>
<td>5</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50–59</td>
<td>12</td>
<td>11</td>
<td>15</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>60–69</td>
<td>17</td>
<td>21</td>
<td>27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>70–83</td>
<td>14</td>
<td>7</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>39</td>
<td>35</td>
<td>41</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>11</td>
<td>9</td>
<td>13</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptom onset to treatment initiation (hr)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤2</td>
<td>6</td>
<td>3</td>
<td>11</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;2–4</td>
<td>22</td>
<td>22</td>
<td>19</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>&gt;4–6</td>
<td>22</td>
<td>19</td>
<td>24</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site of infarct</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anterior</td>
<td>26</td>
<td>24</td>
<td>23</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inferior</td>
<td>18</td>
<td>17</td>
<td>30</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Lateral or posterior</td>
<td>6</td>
<td>3</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infarct-related artery</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Right coronary</td>
<td>17</td>
<td>16</td>
<td>27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Left anterior descending</td>
<td>29</td>
<td>25</td>
<td>23</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Left circumflex</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site of coronary obstruction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proximal</td>
<td>25</td>
<td>25</td>
<td>26</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Middle</td>
<td>16</td>
<td>12</td>
<td>20</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Distal</td>
<td>9</td>
<td>7</td>
<td>8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Killip’s classification</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>40</td>
<td>38</td>
<td>46</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>10</td>
<td>5</td>
<td>7</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>0</td>
<td>1</td>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Forrester’s classification</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>32</td>
<td>32</td>
<td>39</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II</td>
<td>13</td>
<td>8</td>
<td>8</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>III</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Unknown</td>
<td>3</td>
<td>2</td>
<td>4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>History</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angina pectoris</td>
<td>18</td>
<td>16</td>
<td>27</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Previous myocardial</td>
<td>1</td>
<td>5</td>
<td>7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>infarction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypertension</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Various arrhythmias</td>
<td>14</td>
<td>10</td>
<td>16</td>
<td>NS</td>
<td></td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cerebral infarction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Renal disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

two, erroneous administration of the drug intravenously in one, an ambiguity in the serial number of the test sample administered in one, and the erroneous administration of a double dose (eight vials) in one. One hundred forty-eight patients with complete obstruction of the infarct-related artery were analyzed (50 in group H, 44 in group L, and 54 in group U). The clinical profile of the patients is presented in Table 1. The three study groups were not significantly different. Age varied from 39 to 83 years (mean, 61.3 ± 8.9 years); 115 patients were men, and 33 were women. The mean interval between clinical onset of infarction and the initiation of drug administration was 3.8 ± 1.4 hours.

The site of infarction was anterior in 49% of patients, inferior in 44%, and lateral or posterior in 7%. The infarct-related artery was the right coronary artery in 41% of patients, the left anterior descending coronary artery in 52%, and the left circumflex coronary artery in 7%. The site of coronary obstruction was proximal in 51%, middle in 32%, and distal in 16% of patients. Eighty-four percent of the patients were classified as Killip class I, 15% as class II, and 1% as class III; according to Forrester’s classification, 70% were class I, 20% class II, 5% class III, and 6% were unmeasured. Twenty-seven percent of the patients had a history of hypertension, diabetes mellitus, various degrees of atrioventricular block or arrhythmia, pulmonary disease, cerebral infarction, or renal disease. Nine percent of the patients had a previous myocardial infarction, and 41% had angina pectoris.

**Recanalization Rate**

Figure 1 and Table 2 demonstrate the coronary recanalization rates after administration of 1, 2, 3, and 4 vials of the test drug for the different groups. Recanalization (TIMI grade 3) was obtained in 76% of the patients in group H, in 36% in group L, and in 43% in group U with statistically significant differences between groups H and L and groups H and U. Recanalization rates differed between the patients in groups H and L and between those in groups H and U after the third and fourth vials were administered. Grade 3 or 2 recanalization was attained in 90% of the patients in group H, in 59% in group L,
and in 61% in group U. Recanalization rates of grade 2 or more differed between the patients in groups H and L after the third and fourth vials were administered, between those in groups U and L after administration of the second vial, and between those in groups H and U after administration of the fourth vial. Recanalization rates increased in a dose-dependent manner for all three groups.

Table 3 indicates the recanalization rates of the different infarct-related arteries, different sites of coronary obstruction, and different intervals between symptom onset to treatment initiation. Infarct-related coronary artery recanalization rates in the patients of group H were 88% in the right coronary artery and 90% in the left anterior descending coronary artery; in group L, rates were 63% in the right coronary artery and 64% in the left anterior descending coronary artery; and in group U, the rates were 59% in the right coronary artery and 65% in the left anterior descending coronary artery. Proximal, middle, and distal obstruction of the coronary arteries demonstrated respective recanalization rates of 96%, 81%, and 89% in group H; 68%, 42%, and 57% in group L; and 77%, 55%, and 25% in group U; the proximal obstruction sites had the highest recanalization rates.

Shorter intervals of symptom onset to treatment initiation did not significantly improve recanalization rates in any study group.

**Laboratory Data**

Table 4 presents fibrinolysis test results. The fibrinogen level was not different before and after treatment in either group H (187±49 vs. 181±42 mg/dl), group L (178±69 vs. 180±78 mg/dl), or group U (181±51 vs. 162±41 mg/dl). Fibrin(ogen) degradation products were significantly increased in group H (15±17 vs. 41±57 μg/ml) and group U (17±25 vs. 186±286 μg/ml) but not in group L (14±14 vs. 36±103 μg/ml).

The euglobulin lysis time was shortened significantly in all three groups: 3.84±1.98 versus 0.46±1.18 hours in group H, 4.08±2.29 versus 0.33±0.76 hours in group L, and 4.02±1.93 versus 0.74±0.54 hours in group U. There was a significant reduction in α2-plasmin inhibitor in group U (5.68±0.84 vs. 4.40±0.92 mg/ml) and to a lesser degree in group H (5.76±1.16 vs. 4.94±1.12 mg/ml) but not in group L (5.64±1.00 vs. 5.26±0.90 mg/ml).

**Bleeding Complications**

Table 5 presents bleeding complications in six patients (one in group L and five in group U). The patient in group L had bleeding at the puncture site after the catheterization procedure and required a blood transfusion, but immediately after the investigational drug administration, additional heparin and urokinase were infused. The other five patients were administered urokinase with an additional dose of heparin to one patient, urokinase to one, and urokinase and heparin to one.

**Clinical Results 1 Week After Treatment**

There were three reinfarctions (one in group H and two in group U) during the 1-week post-treatment hospitalization. During this period, two patients in
group L died. One died of renal failure, secondary to postoperative complications after surgical closure of a ruptured interventricular septum; the other died of crush syndrome, a complication of the intra-aortic balloon pumping. In group U, three patients died. One death was due to ventricular fibrillation after reinfarction, one was due to cardiac rupture while receiving the second vial of the investigational drug (urokinase), and one was due to renal failure and hematemesis with Mallory-Weiss syndrome.

**Discussion**

Intracoronary administration of urokinase resulted in recanalization rates of approximately 70% in our previous study. In the present study, intracoronary administration of pro-urokinase was used for a comparison with intracoronary urokinase. This study demonstrated an excellent recanalization rate (90%) with high-dose (6,000 units) intracoronary administration of pro-urokinase. A low dose of 3,000 units showed a reduced recanalization rate comparable to that achieved by intracoronary administration of 960,000 IU urokinase, which is the dose currently used in Japan. The present study confirmed that the efficacy of thrombolysis with pro-urokinase was dose dependent up to 6,000 units, a dose that demonstrated a 90% recanalization rate, probably the theoretically expected maximum recanalization rate.

Our previous results also showed that pro-urokinase was an effective thrombolytic and was not associated with systemic activation of the fibrinolytic system, fibrinogen breakdown, or bleeding. Pro-urokinase does not significantly activate plasminogen in plasma in the absence of fibrin, but the addition of a fibrin clot results in efficient fibrinolysis without fibrinogenolysis. In this study, a low dose of pro-urokinase had no significant fibrinolytic effect except on euglobulin lysis time. However, a high dose induced a slight increase in fibrinogen degradation products and a reduction of euglobulin lysis time and α2-plasmin inhibitor. Urokinase showed much more significant generalized effects on the fibrinolytic system.

Bleeding complications were seen in five patients (9%) in group U, but in only one (2.1%) in group L, and in none in group H. Bleeding complications seen in group L occurred after postinvestigational treatment with additional heparin (10,000 IU) and urokinase (240,000 IU i.c.). Furthermore, because no bleeding complications were seen in group H, even after 9,000 units pro-urokinase was administered to four patients (unpublished data from our laboratory), it is unlikely that the current low dose of pro-urokinase induced hemorrhagic complications.

**Table 4. Fibrinolysis Variables**

<table>
<thead>
<tr>
<th>Item</th>
<th>Group</th>
<th>Patients (n)</th>
<th>Before treatment (mean ± SD)</th>
<th>After treatment (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fibrinogen (mg/dl)</td>
<td>H</td>
<td>38</td>
<td>187 ± 49</td>
<td>181 ± 42</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>39</td>
<td>178 ± 69</td>
<td>180 ± 78</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>41</td>
<td>181 ± 51</td>
<td>162 ± 41</td>
</tr>
<tr>
<td>Fibrinogen degradation products (μg/ml)</td>
<td>H</td>
<td>39</td>
<td>15 ± 17</td>
<td>41 ± 57*</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>38</td>
<td>14 ± 14</td>
<td>36 ± 103</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>44</td>
<td>17 ± 25</td>
<td>186 ± 286*</td>
</tr>
<tr>
<td>Euglobulin lysis time (hr)</td>
<td>H</td>
<td>38</td>
<td>3.84 ± 1.98</td>
<td>0.46 ± 1.18*</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>38</td>
<td>4.02 ± 2.29</td>
<td>0.33 ± 0.76*</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>41</td>
<td>4.02 ± 1.93</td>
<td>0.74 ± 0.54*</td>
</tr>
<tr>
<td>α2-Plasmin inhibitor (mg/dl)</td>
<td>H</td>
<td>39</td>
<td>5.76 ± 1.16</td>
<td>4.94 ± 1.12*</td>
</tr>
<tr>
<td></td>
<td>L</td>
<td>39</td>
<td>5.64 ± 1.00</td>
<td>5.26 ± 0.90</td>
</tr>
<tr>
<td></td>
<td>U</td>
<td>42</td>
<td>5.68 ± 0.84</td>
<td>4.40 ± 0.92*</td>
</tr>
</tbody>
</table>

*p<0.01.

**Table 5. Bleeding Complications**

<table>
<thead>
<tr>
<th>Group</th>
<th>Hemorrhage</th>
<th>Onset of bleeding</th>
<th>Treatment</th>
<th>Results</th>
<th>Drugs administered after study</th>
</tr>
</thead>
<tbody>
<tr>
<td>L</td>
<td>Puncture site (mild)</td>
<td>After heparin and urokinase administration</td>
<td>Blood transfusion</td>
<td>Recovered</td>
<td>Heparin Urokinase</td>
</tr>
<tr>
<td>U</td>
<td>Macroscopic hematuria (mild)</td>
<td>2.5 hours after onset of study</td>
<td>Blood transfusion</td>
<td>Recovered</td>
<td></td>
</tr>
<tr>
<td>U</td>
<td>Hematemesis (moderate)</td>
<td>Next day</td>
<td>Blood transfusion</td>
<td>Recovered</td>
<td>Heparin Urokinase</td>
</tr>
<tr>
<td>U</td>
<td>Puncture site (mild)</td>
<td>At end of treatment</td>
<td>Compression</td>
<td>Recovered</td>
<td>Urokinase</td>
</tr>
<tr>
<td>U</td>
<td>Puncture site (massive)</td>
<td>After urokinase infusion</td>
<td>Blood transfusion</td>
<td>Recovered</td>
<td>Urokinase</td>
</tr>
<tr>
<td>U</td>
<td>Hematuria (mild)</td>
<td>After heparin and urokinase administration</td>
<td>. . .</td>
<td>Recovered</td>
<td>Urokinase</td>
</tr>
<tr>
<td>U</td>
<td>Hematemesis (severe)</td>
<td>2.3 hours after onset of study</td>
<td>Blood transfusion</td>
<td>Died</td>
<td>. . .</td>
</tr>
</tbody>
</table>
Clinical Implications and Questions To Be Answered

Because no significant hemorrhagic tendency was documented, pro-urokinase appears to be much safer and more promising for intravenous administration than urokinase in ordinary medical practice, but the safety and effectiveness of the appropriate intravenous dose needs to be confirmed.

The turnover and clearance of pro-urokinase in rabbits and squirrel monkeys demonstrates a rapid initial half-life of about 3 minutes. The main mechanism of removal from circulation is hepatic clearance.22,23 In humans, a biphasic disappearance rate of natural pro-urokinase with an initial half-life of 6 minutes in plasma has been found.24 In this study, the reinfarction rate during the initial 7 days was low, but the use of prolonged infusion of pro-urokinase for further reduction of residual stenosis and to prevent restenosis merits consideration.

In a rabbit jugular vein thrombosis preparation, significant synergism between tissue-type plasminogen activator and pro-urokinase was observed.25 Preliminary results indicated that tissue-type plasminogen activator and pro-urokinase also act synergistically in patients with acute myocardial infarction.26 Low doses of tissue-type plasminogen activator (10 mg) and pro-urokinase (3 mg) were used in the given combination, and coronary reperfusion was obtained within 50 minutes. This synergism was not associated with systemic fibrinolytic breakdown. The combined use of synergic thrombolytic agents may permit a reduction of total administered doses to one fourth of the dose currently used for each agent alone and further decrease the risk of concomitant fibrinogen breakdown,27 but further investigation will be required for confirmation.

Appendix 1: Participating Centers and Collaborators

Hokkaido Circulation Hospital (K. Ohhori, MD).
Iwate Prefectural Central Hospital (K. Tamaki, MD).
Tohoku Kouseinenkin Hospital (T. Meguro, MD).
Honda Memorial Tohoku Cardiovascular Center (M. Honda, MD).
Yamagata Prefectural Central Hospital (K. Yokoyama, MD, T. Miura, MD).
Ohta Nishinouchi Hospital (F. Tsuda, MD, M. Techigawa, MD).
Niigata University Hospital (A. Shibata, MD, A. Hattori, MD, T. Izumi, MD, M. Yamazoe, MD).
Niigata Kobari Hospital (Y. Yazawa, MD, Y. Tamura, MD, A. Tsuchiya, MD).
Niigata Shimin Hospital (N. Higuma, MD, H. Oda, MD).
Ashikaga Red Cross Hospital (M. Chino, MD).
Dokkyo University School of Medicine (M. Yoshimura, MD, K. Ogawa, MD, T. Masuyama, MD).
Dokkyo University School of Medicine, Koshigaya Hospital (Y. Takabatake, MD, S. Morooka, MD).
Chiba Emergency Medical Center (K. Tsunoda, MD).
Funabashi Municipal Medical Center (S. Ozawa, MD).
Chiba Kensei Hospital (T. Hanai, MD).
Surugadai Nihon University Hospital (N. Kajiwara, MD, K. Kanmatsuse, MD).
Showa University Hospital (H. Niitani, MD, Y. Takeyama, MD).
Keio University Hospital (Y. Nakamura, MD, S. Handa, MD).
Tokyo Police Hospital (K. Inoue, MD, K. Ueda, MD, H. Ochiai, MD).
Toranomon Hospital (A. Seki, MD, S. Nakashiki, MD).
Toho University School of Medicine (Y. Yabe, MD).
Nippon Medical School Hospital (H. Hayakawa, MD, N. Hata, MD).
Nippon Medical School Hospital (T. Takano, MD, H. Kurihara, MD, N. Mori, MD).
Juntendo University School of Medicine (H. Yamaguchi, MD, J. Takaya, MD).
Kitasato University Hospital (R. Kikawada, MD, N. Hasegawa, MD).
St. Marianna University School of Medicine (M. Mura-
yama, MD, H. Tochiki, MD).
Shizuoka Prefectural Hospital (T. Kaburagi, MD).
Yaizu Municipal Hospital (F. Nagasaki, MD).
Hamamatsu University School of Medicine (M. Nakashima, MD).
Hamamatsu Rosai Hospital (M. Takahashi, MD).
Hamamatsu Medical Center (C. Fujiwara, MD, H. Hitaya, MD).
Anju Kousei Hospital (T. Takatu, MD).
Aichi Medical University Hospital (T. Watanabe, MD, N. Mizutani, MD).
Nagoya Eksaikai Hospital (Y. Tanahashi, MD, M. Okada, MD, T. Okashiro, MD).
Tousei Public Hospital (K. Sakai, MD, M. Ajioka, MD).
Toyama Medical and Pharmaceutical University (S. Sasa-
ayama, MD, H. Nakajima, MD).
Kanazawa University Hospital (T. Matsuda, MD).
Kanazawa Medical University Hospital (E. Murakami, MD, N. Takekoshi, MD).
Ishikawa Prefectural Central Hospital (T. Ohka, MD, H. Kanaya, MD).
Fuku Medical School Hospital (T. Nakamura, MD, D. Lee, MD).
Fuku Medical School Hospital (S. Miyaho, MD, Y. Kutsumi, MD).
Shiga Prefectural Center for Adult Diseases (H. Uehata, MD).
Kyoto University Hospital (C. Kawai, MD, H. Kambara, MD, T. Fudo, MD).
Takeda Hospital (S. Tamaki, MD).
Kitano Hospital (Y. Ishimura, MD).
Osaka Police Hospital (K. Kodama, MD).
Kinki University Hospital (R. Katori, MD, K. Ishikawa, MD).
Kinki University Hospital (O. Matsuo, MD).
Osaka Prefectural Hospital (K. Ohnishi, MD, T. Houki, MD).
Sakurabashi Watanabe Hospital (T. Minamino, MD, H. Tateyama, MD).
Yao Tokushukai Hospital (T. Hayashi, MD).
Kobe University Hospital (H. Fukuzaki, MD, M. Takeuchi, MD).
Hyogo College of Medicine (T. Iwasaki, MD, N. Yasutomi, MD, K. Kawakami, MD).
Himeji Circulation Center (H. Yoshida, MD, H. Kurogane, MD).
kurashiki Central Hospital (K. Mitsudo, MD).
Hiroshima Municipal Hospital (H. Sato, MD).
Hiroshima Prefectural Hospital (H. Yamashina, MD, M. Yamamoto, MD).
Kure National Hospital (Y. Noma, MD, T. Morimoto, MD).
Saiseikai Shimonoseki General Hospital (E. Hyakuna, MD, H. Ohno, MD).
Kagawa Prefectural Central Hospital (A. Fujii, MD, H. Takeda, MD, Y. Abe, MD).
Komatsu shim Red Cross Hospital (Y. Hisada, MD).
Ehime Prefectural Central Hospital (T. Jyo, MD, K. Nishitani, MD).
Kokura Memorial Hospital (M. Nobuyoshi, MD, G. Kimura, MD).
Fukuoka University Hospital (K. Arakawa, MD, T. Kurihara, MD, H. Miura, MD).
Kagoshima City Medical Association Hospital (M. Tahara, MD, H. Torii, MD).
Kagoshima Seikyo Hospital (K. Miura, MD).
Chuo Hospital (Y. Atsuchi, MD, K. Kubota, MD).

References
22. Collen D, De Cock F, Lijnen HR: Biological and thrombolytic properties of proenzyme and active forms of human urokinase. II. Turnover of natural and recombinant uroki

Key Words: coronary thrombolysis • coronary revascularization • acute myocardial infarction • fibrinogen degradation products
Randomized, double-blinded multicenter study. Comparison of intracoronary single-chain urokinase-type plasminogen activator, pro-urokinase (GE-0943), and intracoronary urokinase in patients with acute myocardial infarction.
H Kambara, C Kawai, N Kajiwara, H Niitani, S Sasayama, K Kanmatsuse, K Kodama, H Sato, M Nobuyoshi and M Nakashima

Circulation. 1988;78:899-905
doi: 10.1161/01.CIR.78.4.899
Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 1988 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/78/4/899

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation is online at:
http://circ.ahajournals.org//subscriptions/